Bayer stock reports Q2 sales growth at EUR 49.23

Bayer stock was trading at EUR 49.23 on Xetra at 11:51 a.m. CEST on September 24, 2026, with a daily change of -0.16 percent. The price stood 8.70 percent below the 52-week high of EUR 53.92, giving investors a clear measure of the gap to the yearly peak.

Q2 sales reach EUR 10.9 billion

Bayer's second-quarter sales increased 2 percent to EUR 10.9 billion, according to the company's Q2 2026 investor materials and Yahoo Finance. That comparison matters because the reported growth came alongside different trends across Bayer's three operating businesses.

Crop Science delivered Q2 sales of EUR 4.9 billion, up 4 percent from the prior-year period. Pharmaceuticals generated EUR 4.5 billion, representing 1 percent growth, while Consumer Health sales increased 3.5 percent, according to Yahoo Finance.

Cash flow remains the key counterweight

For the first six months of 2026, Bayer reported sales of EUR 24.3 billion, up 3 percent, and core EPS of EUR 3.66, also 3 percent above the prior-year period. EBITDA before special items rose 7 percent to EUR 6.6 billion, showing that operating improvement extended beyond the top line.

Cash flow tells a more complicated story. First-half free cash flow was negative EUR 2.7 billion, compared with negative EUR 1.4 billion a year earlier, as litigation-related payments reached EUR 2.5 billion, according to Yahoo Finance. The contrast between higher operating earnings and weaker cash generation is the central financial tension in the current Bayer picture.

Stock stays below yearly high

Bayer stock stood at EUR 49.23 on Xetra on September 24, 2026, with a market capitalization of EUR 48.36 billion. Its 52-week range was EUR 25.78 to EUR 53.92, placing the latest price closer to the upper boundary than the lower one while still 8.70 percent below the high.